Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Factors VIII and IX

Tuesday, December 9, 2008: 1:00 PM-2:30 PM
304-306-308 - South (Moscone Center)
Moderators:
Chia-Ni Lin and Connie H. Miller, PhD
1:00 PM
Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model

Chia-Ni Lin1*, Chung-Yang Kao1*, Chia-Lun Hong1*, Peiqing Ye2*, Carol H. Miao, PhD3, Nobuko Hamaguchi4*, Hua-Lin Wu5*, Guey-Yueh Shi5*, Yung-Li Yang6*, I-Shing Yu1*, Mi-Hua Tao7*, Cheng-Chieh Fang7*, Yi-Lin Liu8*, Katherine A. High, MD9 and Shu-Wha Lin1*

1Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
2Seattle Children's Hospital Research Institute, Seattle, WA
3Seattle Children's Hospital Research Institute and Department of Pediatrics, University of Washington, Seattle, WA
4Department of Biochemistry, Brandeis University, Waltham, MA
5Department of Biochemistry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
6Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
7Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
8Department of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA
9Howard Hughes Medical Institute, The Children's Hospital of Philadelphia, Philadelphia, PA

1:15 PM
Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients:  Correlation of Mutation Type with History of Inhibitor

Connie H. Miller, PhD1*, Craig Hooper, PhD1*, Thomas C. Abshire, MD2, Paula L. Bockenstedt, MD3, Doreen B. Brettler, MD4, Jorge Di Paola, MD5, Gita Massey, MD6, Anne T. Neff, MD7, Amy D. Shapiro, MD8, Michael Tarantino, MD9, Brian M. Wicklund, MD, MPH10, Marilyn J. Manco-Johnson, MD11, Amy L. Dunn, MD2*, Christine Knoll, MD12*, Melissa Creary, MPH1*, Jane Benson1*, Dorothy Ellingsen1*, Jennifer Driggers1* and J. Michael Soucie, PhD1*

1Division of Blood Disorders, NCBDDD, Centers for Disease Control & Prevention, Atlanta, GA
2Emory University School of Medicine, Atlanta, GA
3University of Michigan Medical Center, Ann Arbor, MI
4Memorial Healthcare, Worcester, MA
5Univ. of Iowa Hosp. & Clinics, Iowa City, IA
6VCU, Med. College of VA, Richmond, VA
7Vanderbilt Univ. Med. Ctr., Nashville, TN
8Indiana Hemophilia & Thrombosis Ctr., Indianapolis, IN
9Comprehensive Bleeding Disorders Center, Peoria, IL
10Children's Mercy Hospital, Kansas City, MO
11Mountain State Regional Hemophilia and Thrombosis Center, University of Colorado Denver, Aurora, CO
12Phoenix Children's Hospital, Phoenix, AZ

1:30 PM
HLA-DRB1*1101-Restricted T Cells from Two Unrelated Mild Hemophilia a Inhibitor Subjects with Missense Genotype R593C Respond to the Same Minimal Epitope

Eddie A. James, Ph.D.1*, Simon D. van Haren2*, Ruth A. Ettinger, Ph.D.3*, Arthur R. Thompson, M.D., Ph.D.3, William W. Kwok, Ph.D.1*, Jan Voorberg, Ph.D.2* and Kathleen P. Pratt, Ph.D.3

1Benaroya Research Institute, Seattle, WA
2Sanquin Research, 1066 CX Amsterdam, Netherlands
3Puget Sound Blood Center, Seattle, WA

1:45 PM
De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain

Leonard Moise, Ph.D1*, Jonathan Skupsky, BS2*, Ryan Tassone1*, Julie A McMurry1*, William D Martin3*, Anne S. De Groot, M.D.3* and David W. Scott, PhD2

1Research and Development, EpiVax, Inc., Providence, RI
2School of Medicine, University of Maryland, Baltimore, MD
3Research and Development, EpiVax, Inc., Providence

2:00 PM
AV513 Promotes Tissue Factor-Mediated Coagulation in Fresh Human Whole Blood from Severe and Moderate Hemophilia a Subjects

Jerry Sherman Powell, MD1, Sabine Knappe, PhD2*, Janet A Harrison, BS1*, Susannah Patarroyo-White, BS2*, Kirk Johnson, PhD2 and Srinivasa Prasad, PhD2

1University of California at Davis, Sacramento, CA
2R&D, Avigen Inc, Alameda, CA

2:15 PM
Detection of F8 Mutations by High Resolution Melting (HRM) Analysis

Patricia A Bignell, Clinical, Scientist1*, David M. Keeling, MD2 and Paul Giangrande, MD3*

1Haemophilia Genetics, Oxford Thrombosis and Haemophilia Centre, Oxford, United Kingdom
2Oxford Haemophilia and Thrombosis Centre, Oxford, ARRAY(0xa0899f8)
3Oxford Haemophilia and Thrombosis Centre, Oxford